Though significant progress has been made in understanding the safety and efficacy of PARP inhibitors in the treatment of the aforementioned cancers with frequent BRCA1/2 mutations, the investigation of cutaneous melanoma and its response to PARP inhibition is poorly understood. Here, PARP1 is linked to cutaneous melanoma.